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Acyclovir is an antiviral drug having potent activity against the virus of herpes family and varicella 
zoster. Unfortunately, drug suffers very poor oral bioavailability (15-30%). The main objective of present 
study was to develop acyclovir cocrystals with improved solubility which may result in improvement 
of bioavailability. Hansen solubility approach was used as a tool to predict the cocrystal formation of a 
drug with selected coformer. Cocrystals of acyclovir with various coformers were screened in order to 
enhance their water solubility. Cocrystals of the drug were prepared using various methods like solvent 
evaporation, wet grinding, and antisolvent addition. Formation of cocrystals by solvent evaporation 
method was found to be better method amongst all. Optimization of cocrystal formation was carried out 
by employing different solvents as well as the stoichiometric ratio of acyclovir with that of coformer. 
Synthesis of cocrystals was optimized using water as a solvent system resulted in good agreements. 
The potential cocrystal formation of acyclovir was characterized by IR, PXRD and DSC techniques. 
An in-vitro dissolution study was performed to determine the dissolution rate of cocrystals. The results 
suggest that acyclovir forms cocrystals with tartaric acid and the initial dissolution rate of synthesized 
cocrystals were considerably faster as compared to pure acyclovir.
Uniterms: Acyclovir/study. Acyclovir/dissolution study. Cocrystal/technique. Hansen solubility 
parameters. Solvent evaporation method.
INTRODUCTION
Active Pharmaceutical Ingredients (APIs) are 
commonly administered in the solid dosage form 
as it is the convenient formulation. Drug molecules 
can exist in a variety of different solid forms, where 
each form may display unique physicochemical 
properties such as hygroscopicity, morphology and most 
importantly solubility. Unfortunately, many potentially 
useful compounds with highly desirable molecular 
pharmacological properties may never realize their 
maximum potential because the physical properties 
of the compound display unfavorable bioavailability 
and unacceptable shelf life (Aakeröy, Fasulo, Desper, 
2007). Though numerous strategies like formation of 
salts, solvates, hydrates etc. exist for enhancing the 
bioavailability of drugs. However, these approaches 
depend on the physicochemical properties of the considered 
molecules, which hampers widespread application (Khan, 
Enkelmann, Brunklaus, 2010). 
Indeed, it is well known that fundamental properties 
of (crystalline) materials originate from molecular 
arrangements within the solid (Stahly, 2007). Altering 
the chemical structure of the molecules typically has 
a direct impact on the properties of the particular 
solid. In addition to these established crystalline API 
modifications, pharmaceutical cocrystals, or crystalline 
molecular complexes involving an API, have recently 
attracted interest as an alternative approach (Dunitz, 
2007). A cocrystal may be thought of as a crystalline 
complex of two or more neutral molecular constituents 
bound together in the crystal lattice through noncovalent 
interactions, often including hydrogen bonding (Jones, 
Motherwell, Trask, 2006; Aakeröy, Desper, Fasulo, 2006). 
Pepinsky and Schmidt discovered crystal engineering, 
which is similar to supramolecular synthesis in the solid 
state. Crystal engineering is the technique to generate 
new compounds through self-assembly, instead of using 
traditional multistep covalent synthesis (Bis et al., 2007). 
Modification of the physicochemical properties of 
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APIs could be achieved using pharmaceutical cocrystal 
approach instead of salt formation, and polymorphic and 
amorphous forms, that all have limitations in their utility 
(Masuda et al., 2012).
Acyclovir (CID 2022) is one of the most commonly 
used antiviral drug used in the treatment of herpes simplex 
viral infections. It is also used for the management of the 
disease caused by varicella zoster (chickenpox) and 
herpes zoster (shingles) viruses (Balfour, 1993). Various 
scientific researches in the pharmaceutics have proved 
acyclovir as a potent drug for the above mentioned 
physiological infections. Acyclovir is currently marketed 
as capsules, tablets, suspensions for oral administration. 
Over the half of the dose of currently marketed 
formulation is recovered in the feces Susantakumar, Gaur, 
Sharma (2011). Failure to respond to acyclovir therapy 
may arise due to poor aqueous solubility. Previously 
to improve the solubility, the preparation of a solid 
dispersion, an inclusion complex and a microemulsion 
of acyclovir were reported (Patel, Sawant, 2007; Sachan 
et al., 2010; Rossel et al., 2000). However, the liquid 
formulations suffer from the problems of stability issues 
and are not convenient to administer. Cocrystals of 
acyclovir with l-tartaric acid were reported to improve 
the physical properties of the drug; whereby cocrystals 
were prepared using dimethylformamide and acetic acid 
as solvents (Masuda et al., 2012).
Thus, the development of the readily absorbed 
oral antiviral drug is an unmet need for the viral 
disease. Previous attempts have been made to improve 
the bioavailability of acyclovir by formulating water-
dispersible tablets which facilitate to incorporate higher 
dose; up to 800 mg. The tablet, however, does not 
improve the bioavailability of the drug. Acyclovir sodium 
is available as a powder for injection or intravenous 
infusion in dosages of 25 and 50 mg/mL. The solubility 
of acyclovir sodium salt is more than 100 mg/mL at 25 
°C in water but at pH 7.4 and 37 °C, the drug is almost 
completely unionized and has a maximum solubility 
of 2.5 mg/mL (Bethesda, 1997). In patients with renal 
impairment, acyclovir is associated with neurotoxicity 
when administered with intravenous route, but if given 
orally, the doses are typically low and serious adverse 
effects are extremely rare (Tilson, Engle, Andrews, 
1993).
Acyclovir exists in four anhydrous forms and two 
hydrated forms (Kristl et al., 1996; Lutker et al., 2011; 
Bruni et al., 2013). The hydrated and anhydrated forms 
of acyclovir reported till now suffered from poor water 
solubility (Kristl et al., 1996). According to different 
Pharmacopoeias, acyclovir is “slightly solubility in 
water” at 22-25 °C and solubility ranges from 1.2 to 1.6 
mg/mL. The solubility of the drug varies slightly with 
pH and lowest solubility of 2.3mg/mL reported at pH 
5.8 at 37 °C (Luengo et al., 2002, Susantakumar, Gaur, 
Sharma, 2011).
The aim of the study was to prepare cocrystals of 
acyclovir with different coformers (Figure 1). For the 
said purpose, first Hansen Solubility Parameters (HSPs) 
approach was used to investigate the miscibility of a drug 
and coformer. To predict the miscibility of a drug with 
excipients in different formulation like solid dispersions, 
HSPs have been widely used (Greenhalgh et al., 1999). 
HSPs could predict the compatibility of pharmaceutical 
materials and for pre-formulation and formulation 
development of tablets. The HSPs of the coformers 
and acyclovir were calculated using group contribution 
methods. Based on the HSPs calculations, coformers were 




Acyclovir was donated by Cadila Healthcare 
(Zydus), Ahmedabad. Coformers and Other reagents were 
purchased from S.d Fine Chem Ltd.
Methods
HSPs calculations of Acyclovir
The group contribution method was employed 
to calculate HSPs of the acyclovir which only requires 
knowledge of the compound’s chemical structure. 
According to HSPs, the total force of the various 
interactions can be divided into partial solubility 
FIGURE 1 - Chemical structure of acyclovir and coformers used 
in the study.
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parameters, i.e. dispersion (δd), Polar (δp) and hydrogen 
bonding (δh) (Fedors, 1974; Van Krevelen, 1990).
Van Krevelen–Hoftyzer and Fedors combined 
group contribution methods were used to calculate the 
partial solubility parameters for acyclovir and different 
coformers. Compounds with similar δ values are likely to 
be miscible (Özdemir, Güner 2007).
 δd = ΣFdi /ΣVi (1)
 δP = (ΣFPi
2)1/2 / ΣVi (2)
 δh = (ΣFhi / ΣVi)
1/2 (3)




 δѵ = (δd
2 + δp
2)1/2 (5)
where i is the structural group within the molecule, Fdi is 
the group contribution to the dispersion forces, Fpi is the 
group contribution to the polar forces, Fhi is the group 
contribution to the hydrogen bonding energy, Vi is the 
group contribution to the molar volume.
Different approaches were used to estimate the 
miscibility of compounds as discussed by Mohammad, 
Alhalaweh, Velaga (2011) The miscibility of two 
compounds (∆δ) can be calculated using the following 
equation given by Van Krevelen and Hoftyzer (Alhalaweh, 
Alzghoul, Kaialy, 2014). Good miscibility can be achieved 
if ∆δ ≤ 5 MP0.5 (Guner, 2004).
 ∆δ = [(δd2 – δd1)
2 + [(δp2 – δp1)
2 + [(δh2 – δh1)
2]1/2 (6)
The effects of δd and δp are thermodynamically 
similar, and the effect of δh is different in nature. So volume 
dependent solubility parameter was calculated by using 
following equation (Maniruzzaman et al., 2013).
 δv = (δd
2 + δp
2) 1/2 (7)
Prediction of miscibility between two compounds 
can also be determined by Ra(v) factor. 
 Ra(v) = [4(δv2 – δv1)
2 + (δh2 – δh1)
2] 1/2 (8)
Two components are likely to be miscible if Ra(v) ≤ 
5.6 MP0.5 as reported by Mohammad, Alhalaweh, Velaga 
(2011).
Total solubility parameter (∆δt) between the drug 
and the carriers can be applied as a tool to predict the 
miscibility of two compounds. 
 ∆δt = |δt2 – δt1| (9)
where t1 and t2 are carriers and drug respectively and 
compounds with ∆δt<7MP0.5 are miscible with each other 
(Mohammad, Alhalaweh, Velaga, 2011).
Preparation of acyclovir cocrystals
Synthesis of cocrystals of acyclovir was carried 
out using various methods like solvent evaporation, 
wet grinding, and antisolvent addition. Screening of 
cocrystal formation was carried out by employing different 
coformers in optimum molar ratio with that of acyclovir 
using different solvents (Karki et al., 2007).
Cocrystallization of acyclovir-tartaric acid
A 1:6 mixture of acyclovir and tartaric acid was 
dissolved in water and stirred continuously at 70 °C. 
After 30 minutes remaining solvent was evaporated to 
3/4th of its volume at 70 °C and transferred immediately 
to the cold environment i.e. 0 °C. Obtained crystals were 
filtered and dried in a desiccator over silica gel at room 
temperature.
Characterization of Cocrystal formation
Formation of cocrystals was primarily confirmed by 
comparing the melting points (Scientific MP1) of cocrystal 
with that of pure drug and respective coformer. 
The shape of cocrystals was compared with the pure 
drug and coformer using microscopic inspection (LYNX 
XSP-35) as a primary evaluation parameter.
Infra Red spectroscopy
IR spectra of samples were recorded on FT/IR-6100 
(JASCO Corporation, Tokyo, Japan) by KBr dispersion 
method. The spectra were collected over the range of 
4000-1000 cm−1 in 32 scans, with a resolution of 4 cm−1 
for each sample.
Differential Scanning Calorimetry
DCS technique was used to identify the difference in 
the amount of heat required to increase the temperature of 
a sample as a function of temperature. The samples were 
analyzed by Differential Scanning Calorimeter (DSC-60) 
over the range of 50-300 °C at the rate of 20 °C per minute.
Powder X-ray diffractometry (PXRD)
X-ray powder diffraction of the synthesized 
cocrystals was collected using spinner PW3064 at the 
minimum step size 2Theta:0.001 and minimum step size 
Omega: 0.001.
In vitro dissolution study
The in vitro dissolution assay was performed 
to check the dissolution rate of cocrystals initially in 
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triplicate (Kadu et al. 2011). 50 mg of each acyclovir and 
cocrystals were used to carry out the dissolution study 
using dissolution test apparatus (basket method). The 
dissolution was carried out by taking medium consisted 
of 900 mL of phosphate buffer at pH 6.8 equilibrated 
at 37 °C ± 0.5 °C with a stirring speed of 50 rotations 
per minute. At definite time interval, 10 mL of solution 
was withdrawn to measure the absorbance and 10 mL 
of fresh dissolution medium was added to maintain the 
volume. Aliquots withdrawn were analyzed under UV 
spectrophotometer to check the absorbance at 255 nm. 
The dissolution study carried out up to 1 hour. To convert 
the absorbance of the samples in terms of concentration 
of the drug, a standard curve of the pure drug acyclovir 
was obtained (Doile et al., 2008). 
RESULTS AND DISCUSSION
Miscibility prediction of coformers with acyclovir 
using HSPs method
A diverse set of thirty-four coformer with the ability 
to form hydrogen bonds with acyclovir were used in the 
study. The HSPs calculations of acyclovir are summarized 
in Table I as an example using the group contribution 
method following the combined models of Fedors and 
Van Krevelen–Hoftyzer. The HSPs calculations of 
acyclovir and the coformers were carried out using Van 
Krevelen–Hoftyzer, Bagley and Greenhalgh methods to 
study miscibility of two components (Greenhalgh et al., 
1999; Van Krevelen, 1990). 
TABLE I - HSPs and molar volume calculations for acyclovir according to the Hoftyer-Van Krevelen method
 
Group Frequency Fdi (J1/2 cm3/2 mol-1) Fpi (J1/2 cm3/2 mol-1) Fhi (J1/2 cm3/2 mol-1) V (cm3 mol-1)
-NH2 1 280 0 8400 19.2
-NH 1 160 210 3100 4.5
 
1 290 770 2000 10.8
-CH2- 3 270x3 = 810 0 0 16.1x3 = 48.3
-O- 1 100 400 3000 3.8
-OH 1 210 500 20,000 10.0
 
2 20 x2 =40 800 5000 5.0x2 = 10
 
1 20 800 5000 -9.0
=CH- 1 200 0 0 13.5
 
3 210 0 0 -16.5
Ring 2 190x2 = 380 0 0 16x2 = 32
Conjugation in Ring 
for each double bond
3 - - - -2.2x3 = -6.6
135.6
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From correlation plots of δh2 – δh1, δp2 – δp1 and δd2 
– δd1 Vs ∆δ, it was observed that δh2 – δh1 correlated well 
with ∆δ as the correlation coefficient was found to be 
0.939. The results of correlation plot indicate contribution 
of hydrogen bonding for miscibility of two components. 
According to the criterion of Greenhalgh et al. 
(1999) (i.e. ∆δt<7 MP0.5) eighteen out of thirty-two 
coformers were predicted to be miscible with acyclovir. 
The predicted values for miscibility of compounds 
possessing carboxylic acid as a functional group was found 
to be satisfactory as coformers with drug according to the 
criterion of Bagley et al. (1971), Greenhalgh et al. (1999), 
and Van Krevelen (1990) and Hoftyzer for ∆δt, ∆δ and 
Ra(v). The predicted miscibility of the selected coformers 
(Table II) with the drug was also verified experimentally 
in triplicate. 
Cocrystals screening and physical 
characterization
Synthesis of cocrystals of acyclovir with coformer 
using methods like solvent evaporation, wet grinding, and 
an anti-solvent addition was carried out. Optimization of 
synthesis of cocrystals was performed by utilizing various 
solvents like ethanol, ethyl acetate, acetone, water and 
isopropyl alcohol as summarized in Table III. 
TABLE II - Physical properties of cocrystal formers
Coformers Pub Chem ID Molecular weight (g/mol) Melting point (°C)
Tartaric acid CID 875 150 171
Succinic acid CID 1110 118.09 185
Malonic acid CID 867 104.06 135
Glutaric acid CID 743 132.12 95
Adipic acid CID 196 146.14 152
Citric acid CID 311 192.12 156
4-amino benzamide CID 76079 136.15 181
4-hydroxy benzamide CID 65052 137.14 161
4-amino benzoic acid CID 978 137.14 187
Malic acid CID 525 134.87 130
Oxalic acid CID 971 126.08 102
Fumaric acid CID 444972 116.07 287
TABLE III - Screening of cocrystal formation using different solvents
Cocrystal former Water Ethanol Acetone Ethyl acetate Isopropyl alcohol
Tartaric acid ACC DF PM PM PM
Succinic acid DF DF NT NT NT
Malonic acid ACC DF DF DF PM
Glutaric acid DF DF NT NT NT
Adipic acid ACC DF DF DF PM
Citric acid DF DF PM PM NT
4-amino benzamide PM DF NT PM NT
4-hydroxy benzamide PM NT NT NT NT
4-amino benzoic acid PM NT NT NT NT
Malic acid DF DF PM NT NT
Oxalic acid DF DF PM NT NT
Fumaric acid DF Cocrystals* DF DF DF
ACC: Acyclovir cocrystals, DF: Different crystal form or non-uniform crystals, PM: Physical Mixture, (NT) Experiment not 
conducted, Cocrystals*: Not reproducible
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It was observed that using ethanol as a solvent for 
cocrystallization suffered the early precipitation of the 
acyclovir, which was confirmed by microscopic inspection 
indicated non-uniform shape of crystals. The synthesis 
of cocrystal was optimized using water as a solvent as 
it is clean, cheap and ultimate solvent for replacing the 
traditional polar aprotic solvents. As the water is used 
throughout the process, it claims the green chemistry 
approach for the synthesis of cocrystals. 
Solvent evaporation using water as a solvent gave 
the satisfactory results for the formation of cocrystals 
of acyclovir. Preliminary evaluation of formation of 
cocrystals was carried out by comparison of melting points 
of pure drug, coformers, and cocrystals.
The shape of synthesized cocrystals was observed 
under the microscope for their uniformity and crystal habit. 
Microscopy study revealed the formation of cocrystal with 
glutaric acid not showing a comparable difference in the 
crystal shape with that of pure glutaric acid. While the 
formation of cocrystals with tartaric acid, succinic acid, 
malonic acid and adipic acid exhibited good results.
Different methods were used for the synthesis of 
cocrystals of acyclovir. Solvent evaporation method was 
found to be a more efficient method for cocrystallization. 
Acyclovir has 3 hydrogen bond donor and 4 
hydrogen bond acceptor sites for the formation of the 
hydrogen bond with coformer. The ratio of coformer 
with that of acyclovir was optimized for the formation of 
cocrystals.
A stoichiometric amount of acyclovir and coformer 
was taken for cocrystal synthesis by solvent evaporation 
method. Cocrystallization of a drug with selected coformer 
in a ratio of 1:6 (acyclovir:cocrystal former) afforded 
cocrystal formation. 
Differential Scanning Calorimetry (DSC) was 
performed for the pure drug acyclovir (Rajurkar, Gite, 
Ghawate, 2015), coformer and synthesized cocrystals 
over the range of 50-300 °C at the rate of 20 °C per 
minute. DSC peak of CA1 (acyclovir+tartaric acid), CA3 
(acyclovir+malonic acid) and CA5 (acyclovir+adipic 
acid) was different as compared to pure drug and coformer 
suggested the formation of new solid phase.
PXRD diffractogram of cocrystals of acyclovir 
with tartaric acid as compared to pure drug and coformer 
resembled completely new patterns indicating generation 
of new solid forms. PXRD patterns of CA3 and CA5 
suggested the physical mixture of acyclovir with 
coformers, although a single distinguish DSC peak 
obtained as compared to acyclovir and respective 
coformers. DSC analysis and PXRD patterns revealed the 
formation of cocrystals of acyclovir with tartaric acid as 
shown in Figures 2 and 3.
In vitro dissolution assay
Synthesized cocrystals were evaluated by in-vitro 
dissolution assay. Cumulative % drug release of synthesized 
cocrystals was obtained by dissolution study and was 
compared with that of pure API. One hour dissolution study 
was performed for both pure acyclovir and cocrystals. A 
standard curve of acyclovir is shown in Figure 4. 
The final results were obtained in terms of cumulative 
% drug release. Significant increase in the cumulative % 
drug release was observed for cocrystals as compared to 
acyclovir. From dissolution study, it was observed that 
FIGURE 2 - PXRD patterns of acyclovir.
FIGURE 3 - PXRD patterns of CA1 (Acyclovir : Tartaric acid 
(1:6)).
FIGURE 4 - Standard curve of acyclovir.
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after 1 min pure acyclovir showed the release of 6.82% 
into the medium. While CA1 showed much higher drug 
release of 26.69% as compared to acyclovir as shown in 
Figure 5. From dissolution study, it was revealed that the 
synthesized cocrystals exhibited rapid drug release as 
compared to acyclovir. Percentage drug release of pure 
acyclovir after 30 min found to be 71.77% and that of 
cocrystals releases was found to be 83-88%. 
CONCLUSION
In our study, we used HSPs approach as a tool to 
predict the miscibility of cocrystal former and acyclovir. 
Selection of coformer was performed based on the 
prediction of HSPs. Cocrystals of acyclovir with improved 
solubility were developed using solvent evaporation 
method using water as a solvent. The ratio of drug to that 
of coformer was optimized by considering the number 
of theoretical hydrogen bond donor sites and hydrogen 
bond acceptor sites in acyclovir and cocrystal formers. 
The solid analysis was performed using Melting Point, 
Microscopic evaluation, IR, DSC and PXRD techniques. 
In vitro dissolution, assay was performed to check the 
dissolution of cocrystal initially. The study suggested the 
initial solubility of cocrystals was considerable higher as 
compared to pure drug. Hence synthesis of cocrystals of 
acyclovir can be considered as a promising approach for 
increasing the solubility.
ACKNOWLEDGEMENTS
The authors are grateful to Cadila Healthcare 
(Zydus), Ahmedabad for providing acyclovir as a gift 
sample. 
REFERENCES
AAKERÖY, C.B.; DESPER, J.; FASULO, M.E. Improving 
success rate of hydrogen-bond driven synthesis of co-
crystals. Cryst.Eng.Comm., v.8, n.8, p.586, 2006. 
AAKERÖY, C.B., FASULO, M.E., DESPER, J. Cocrystal or salt: 
does it really matter? Mol. Pharm., v.4, n.3, p.317-322, 2007. 
ALHALAWEH, A.; ALZGHOUL, A.; KAIALY, W. Data mining 
of solubility parameters for computational prediction of 
drug-excipient miscibility. Drug Develop. Ind. Pharm., 
v.40, n.7, p.904-909, 2014.
BALFOUR, H.H. Current management of varicella zoster virus 
infections. J. Med. Virol., v.41, n.S1, p.74-81, 1993.
BETHESDA, M.D. American hospital formulary service. AHFS 
Drug Information®97. Am. Soc. Health-Syst. Pharmacol., 
v.440-449, p.2678-2680, 1997.
BIS, J.A.; VISHWESHWAR, P.; WEYNA, D.; ZAWOROTKO, 
M.J. Hierarchy of supramolecular synthons: persistent 
hydroxyl···pyridine hydrogen bonds in cocrystals that contain 
a cyano acceptor. Mol. Pharm., v.4, n.3, p.401-416, 2007.
BRUNI, G.; MAIETTA, M.; MAGGI, L.; MUSTARELLI, 
P.; FERRARA, C.; BERBENNI, V.; MILANESE, 
C.;  GIRELLA, A.;  MARINI,  A .  Preparation and 
physicochemical characterization of acyclovir cocrystals 
with improved dissolution properties. J. Pharm. Sci., v.102, 
n.11, p.4079-86, 2013. 
DOILE, M.M.; FORTUNATO, K.A.; SCHMÜCKER, I.C.; 
SCHUCKO, S.K.; SILVA, M.A.S.; RODRIGUES, P.O. 
Physicochemical properties and dissolution studies of 
dexamethasone acetate-β-cyclodextrin inclusion complexes 
produced by different methods. AAPS PharmSciTech., v.9, 
n.1, p.314-321, 2008. 
DUNITZ, J.D. Crystal and co-crystal: a second opinion. Cryst.
Eng.Comm., v.5, n.91, p.506, 2003. 
FEDORS, R.F. A method for estimating both the solubility 
parameters and molar volumes of liquids. Polym. Eng. Sci, 
v.14, n.2, p.147-154, 1974. 
GREENHALGH, D.J.; WILLIAMS, A.C.; TIMMINS, P.; 
YORK, P. Solubility parameters as predictors of miscibility 
in solid dispersions. J. Pharm. Sci., v.88, n.11, p.1182-1190, 
1999.
FIGURE 5 - Cumulative % release of CA1 in comparison with 
acyclovir.
J. K. Savjani, C. Pathak734
GÜNER, A. The algorithmic calculations of solubility parameter 
for the determination of interactions in dextran/certain polar 
solvent systems. Eur. Polym. J., v.40, n.7, p.1587-1594, 
2004. 
JONES, W.; MOTHERWELL, W.D.S.; TRASK, A.V. 
Pharmaceutical cocrystals: an emerging approach to 
physical property enhancement. MRS Bull., v.31, n.11, 
p.875-879, 2006. 
KADU, P.J.; KUSHARE, S.S.; THACKER, D.D.; GATTANI, 
S.G. Enhancement of oral bioavailability of atorvastatin 
calcium by self-emulsifying drug delivery systems 
(SEDDS). Pharm. Dev. Tech., v.16, n.1, p.65-74, 2011.
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